Fractyl has the GUTS: Obesity and diabetes biotech charts $99M IPO

Kyle LaHucik

Senior Reporter

Fractyl Health is attempting to ride the waves created by last week’s successful biotech IPOs for cancer drugmakers CG Oncology and ArriVent Biopharma.

The cardiometabolic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Fractyl has the GUTS: Obesity and diabetes biotech charts $99M IPO

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Immunology biotech Inmagene to join Nasdaq through reverse merger with what's left of Ikena

Fractyl has the GUTS: Obe­si­ty and di­a­betes biotech charts $99M IPO

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

Fractyl has the GUTS: Obesity and diabetes biotech charts $99M IPO

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Immunology biotech Inmagene to join Nasdaq through reverse merger with what's left of Ikena